NO

Novartis

Every trial this sponsor leads in the registry, and everything it has published.

3,405All trials
Recruiting142
Recruited141
Not yet recruiting23
By invitation1
Completed2,586
Stopped507
Other5

307 active · 9% of this sponsor’s registry footprint

Oncology116 trials
Neurology33 trials
Immunology & Inflammation29 trials
Dermatology23 trials
Cardiovascular20 trials
Metabolic/Endocrine/Nutrition18 trials
Renal & Urology15 trials
Haematology13 trials

Not shown above: 1 Phase 1 healthy-volunteer trial and 24 trials whose condition matched no therapy area.

Trials by phase

Phase 1647
Phase 2945
Phase 31,118
Phase 4539
Unphased156

Pipeline by phase · 103 drugs in active development

Phase 3 · 22 drugs

Remibrutinib (LOU064)20 trials · 11 recruitingest. Nov 2026
Ianalumab (VAY736)17 trials · 6 recruitingest. Oct 2026
Iptacopan (LNP023)14 trials · 9 recruitingest. Oct 2026
Alpelisib9 trials · 2 recruitingest. Jan 2027
Pelabresib7 trials · 4 recruitingest. Nov 2026
Pelacarsen6 trials · 4 recruitingest. Feb 2028
Opnurasib (JDQ443)5 trials · 1 recruitingest. Sept 2026
Tisagenlecleucel (CTL019)5 trials · 3 recruitingest. Mar 2027

Phase 2 · 26 drugs

Rapcabtagene Autoleucel (YTB323)9 trialsest. Sept 2026
GIA6323 trials · 2 recruitingest. May 2027
JSB4623 trialsest. Jan 2027
QCZ4843 trials · 2 recruitingest. Jan 2027
Arumakimig (MAS825)2 trials · 1 recruitingest. Apr 2027
PKN6052 trials · 1 recruitingest. Feb 2027
VHB9372 trials · 1 recruitingest. Sept 2028
ABL001/Asciminib1 trial · 1 recruitingest. Feb 2029

Phase 1 · 37 drugs

PIT5653 trialsest. Jan 2027
Tulmimetostat3 trials · 3 recruitingest. Nov 2029
[68Ga]Ga-DWJ1552 trials · 2 recruitingest. Jun 2028
[68Ga]Ga-NeoB2 trialsest. Dec 2026
[177Lu]Lu-NeoB1 trialest. Nov 2028
[68Ga]Ga-NNS3091 trial · 1 recruitingest. Jan 2031
225^Ac-PSMA-6171 trialest. Jan 2027

Phase 4 · 18 drugs

Inclisiran16 trials · 6 recruitingest. Oct 2026
177Lu-PSMA-617 (AAA617)9 trials · 3 recruitingest. Oct 2026
Ribociclib (LEE011)9 trials · 4 recruitingest. Feb 2027
Asciminib7 trials · 4 recruitingest. Sept 2027
secukinumab4 trials · 2 recruitingest. Feb 2028
Crizanlizumab3 trials · 2 recruitingest. Jul 2029
dabrafenib3 trials · 1 recruitingest. Nov 2026
Ofatumumab3 trialsest. Apr 2027

Not counted above: 3 unphased interventions.

Active trials only, code names and brands merged. 2,586 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 3 of 10 curated

Breast cancer (Oncology)28 trials · 15 recruiting · 12 drugs0.9% of landscape
Non-small cell lung cancer (Oncology)11 trials · 7 recruiting · 7 drugs0.8% of landscape
Atopic dermatitis (Dermatology)1 trial · 1 drug0.6% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon